Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and IMMUNOPLANT.

Man patients with MIBC are ineligible for or refuse SOC cisplatin. SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic ...

In premenopausal women with early breast cancer, survival is not affected by fertility preservation procedures, researchers report.

In non-low-risk DCIS of the breast, the addition of a TBB of radiation following postoperative WBI is associated with reduced local recurrence.

Patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer can be safely treated without chemotherapy.

EPIK-B5 study evaluated alpelisib plus fulvestrant vs placebo for efficacy and safety in patients with PIK3CA-m HR+, HER2− advanced breast cancer who had progressed on a CDK4/6 inhibitor and an ...

Less-invasive lymph node procedures are noninferior to axillary lymph node dissection for 3-year recurrence outcomes in breast cancer patients.